European Union - English - EMA (European Medicines Agency)

glaxosmithkline biologicals s.a. - split influenza virus, inactivated, containing antigen: a/vietnam/1194/2004 (h5n1) like strain used (nibrg-14) - influenza, human; immunization; disease outbreaks - vaccines - active immunisation against h5n1 subtype of influenza a virus.this indication is based on immunogenicity data from healthy subjects from the age of 18 years onwards following administration of two doses of vaccine prepared from a/vietnam/1194/2004 nibrg-14 (h5n1) (see section 5.1).prepandemic influenza vaccine (h5n1) (split virion, inactivated, adjuvanted) glaxosmithkline biologicals 3.75 µg should be used in accordance with official guidance.

European Union - English - EMA (European Medicines Agency)

glaxosmithkline biologicals s.a. - split influenza virus, inactivated, containing antigen: a/vietnam/1194/2004 (h5n1) like strain used (nibrg-14) - influenza, human - vaccines - prophylaxis of influenza in an officially declared pandemic situation. pandemic influenza vaccine should be used in accordance with official guidance.

European Union - English - EMA (European Medicines Agency)

glaxosmithkline biologicals s.a. - split influenza virus, inactivated, containing antigen: a/vietnam/1194/2004 (h5n1) like strain used (nibrg-14) - influenza, human, immunization, disease outbreaks - vaccines, - prophylaxis of influenza in an officially declared pandemic situation. pandemic influenza vaccine should be used in accordance with official guidance.,

Israel - English - Ministry of Health

glaxo smith kline (israel) ltd - mupirocin - ointment - mupirocin 2 %w/w - mupirocin - mupirocin - bactroban is a topical antibacterial agent, active against those organisms responsible for the majority of skin infections. bactroban dermal is used for skin infections, e.g. impetigo, folliculitis, furunculosis.

Israel - English - Ministry of Health

glaxo smith kline (israel) ltd - clobetasone butyrate - cream - clobetasone butyrate 0.05 %w/w - clobetasone - clobetasone - eumovate cream is a moderately potent topical corticosteroid indicated for adults, elderly, children and infants for the relief of the inflammatory and pruritic manifestations of steroid responsive dermatoses.these include the following:- atopic dermatitis- irritant or allergic contact dermatitis- seborrhoeic dermatitis- nappy rash- photodermatitis- otitis externa- prurigo nodularis- insect bite reactionseumovate may be used as maintenance therapy between courses of one of the more potent topical steroids.

Israel - English - Ministry of Health

glaxo smith kline (israel) ltd - betamethasone as valerate - cream - betamethasone as valerate 0.1 %w/w - betamethasone - betamethasone - betamethasone valerate is a potent topical corticosteroid indicated for adults, elderly and children over 1 year for the relief of the inflammatory and pruritic manifestations of steroid responsive dermatoses.

Israel - English - Ministry of Health

glaxo smith kline (israel) ltd - betamethasone as valerate - ointment - betamethasone as valerate 0.1 %w/w - betamethasone - betamethasone - betamethasone valerate is a potent topical corticosteroid indicated for adults, elderly and children over 1 year for the relief of the inflammatory and pruritic manifestations of steroid responsive dermatoses.these include the following:atopic dermatitis (including infantile atopic dermatitis)nummular dermatitis (discoid eczema)prurigo nodularispsoriasis (excluding widespread plaque psoriasis)lichen simplex chronicus (neurodermatitis) and lichen planusseborrhoeic dermatitisirritant or allergic contact dermatitisdiscoid lupus erythematosusadjunct to systemic steroid therapy in generalised erythroderma

Israel - English - Ministry of Health

glaxo smith kline (israel) ltd - lamivudine - tablets - lamivudine 100 mg - lamivudine - lamivudine - zeffix is indicated for the treatment of chronic hepatitis b associated with the evidence of hepatitis b viral (hbv) replication and active liver inflammation in adults and also in children and adolescents aged 2 to 17 years old.

Israel - English - Ministry of Health

glaxo smith kline (israel) ltd - pneumococcal polysaccharide serotype 1; pneumococcal polysaccharide serotype 14; pneumococcal polysaccharide serotype 18c; pneumococcal polysaccharide serotype 19 f; pneumococcal polysaccharide serotype 23f; pneumococcal polysaccharide serotype 4; pneumococcal polysaccharide serotype 5; pneumococcal polysaccharide serotype 6b; pneumococcal polysaccharide serotype 7f; pneumococcal polysaccharide serotype 9v - suspension for injection - pneumococcal polysaccharide serotype 19 f 3 mcg / 0.5 ml; pneumococcal polysaccharide serotype 1 1 mcg / 0.5 ml; pneumococcal polysaccharide serotype 4 3 mcg / 0.5 ml; pneumococcal polysaccharide serotype 5 1 mcg / 0.5 ml; pneumococcal polysaccharide serotype 6b 1 mcg / 0.5 ml; pneumococcal polysaccharide serotype 7f 1 mcg / 0.5 ml; pneumococcal polysaccharide serotype 9v 1 mcg / 0.5 ml; pneumococcal polysaccharide serotype 14 1 mcg / 0.5 ml; pneumococcal polysaccharide serotype 18c 3 mcg / 0.5 ml; pneumococcal polysaccharide serotype 23f 1 mcg / 0.5 ml - pneumococcus, purified polysaccharides antigen conjugated - pneumococcus, purified polysaccharides antigen conjugated - active immunisation against invasive disease, pneumonia and acute otitis media caused by streptococcus pneumoniae serotypes 1, 4, 5, 6b, 7f, 9v, 14, 18c, 19f, and 23f in infants and children from 6 weeks up to 5 years of age.the use of synflorix should be determined on the basis of official recommendations taking into consideration the impact on pneumococcal diseases in different age groups as well as the variability of the epidemiology in different geographical areas.10.07.2017 בקשה לשינוי משטר מינוןthree-dose primary seriesthe recommended immunisation series to ensure optimal protection consists of four doses, each of 0.5 ml. the primary infant series consists of three doses with the first dose usually given at 2 months of age and with an interval of at least 1 month between doses. the first dose may be given as early as six 6 weeks of age. a booster (fourth) dose is recommended at least 6 months after the last priming primary dose and may be given from the age of 9 months onwards (preferably between 12 and

Israel - English - Ministry of Health

glaxo smith kline (israel) ltd - live attenuated measles virus; live attenuated mumps virus; live attenuated rubella virus; live attenuated varicella virus - powder and solvent for solution for injection - live attenuated measles virus 10^ 3.0 ccid50; live attenuated mumps virus 10^ 4.4 ccid50; live attenuated rubella virus 10^ 3.0 ccid50; live attenuated varicella virus 10^ 3.3 pfu - measles, combinations with mumps, rubella and varicella, live attenuated - measles, combinations with mumps, rubella and varicella, live attenuated - priorix-tetra is indicated for active immunisation against measles, mumps, rubella and varicella in children from the age of 12 months up and including 12 years of age.